Medical device company ResMed (NYSE:RMD) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 11% year on year to $1.42 billion. Its non-GAAP profit of $2.81 per share was 3.2% above analysts’ consensus estimates.
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at ResMed (NYSE:RMD) and its peers.
In a landmark shift for preventative medicine, researchers at Stanford University have unveiled SleepFM, a pioneering multimodal AI foundation model capable of predicting over 130 different health conditions from just one night of sleep data. Published in Nature Medicine on January 6, 2026, the model marks a departure from traditional sleep tracking—which typically focuses on [...]
Since July 2025, ResMed has been in a holding pattern, floating around $254.41. The stock also fell short of the S&P 500’s 11.3% gain during that period.
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments.
Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns.
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising
as the industry has posted a 15.6% gain over the past six months, beating the S&P 500 by 1.7 percentage points.
New York, NY – December 10, 2025 – The U.S. stock market is currently experiencing a robust rally, with major indices positioned tantalizingly close to their all-time highs. This bullish sentiment, culminating in a significant surge on December 10, 2025, is largely propelled by the Federal Reserve's recent interest rate cut
Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top S&P500 gainers and losers in today's pre-market session.
The corporate earnings landscape as of December 9, 2025, presents a complex yet compelling narrative. While the third quarter of 2025 largely concluded with robust performance across the S&P 500, marked by significant earnings and revenue beats, early insights and guidance for Q4 2025 and fiscal year 2026 reveal
ResMed (RMD) is a high-quality dividend stock with a secure payout, strong profitability, and a rock-solid balance sheet, ideal for sustainable passive income growth.
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Large-cap stocks usually command their industries because they have the scale to drive market trends.
The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.
ResMed faces an uncertain future as GLP-1 weight loss drugs threaten to reduce demand for sleep apnea devices, creating a complex investment dilemma for shareholders of the CPAP machine leader.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
ResMed (RMD) offers a reliable dividend with strong growth potential. Its low payout ratio, high profitability, and financial health support future dividend increases.
